Affinity Asset Advisors LLC Purchases 60,000 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• Affinity Asset Advisors LLC increased its holdings in Kymera Therapeutics, Inc. by 150%, acquiring an additional 60,000 shares, bringing its total to 100,000 shares valued at approximately $2.7 million.
• Kymera Therapeutics recently reported a quarterly loss of ($0.95) EPS, missing expectations and seeing a revenue drop of 55.1% year-over-year.
• Several analysts have given Kymera Therapeutics a "buy" rating, with price targets ranging from $55 to $70, while the stock currently has a consensus target of $58.76.

Affinity Asset Advisors LLC grew its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 150.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 100,000 shares of the company's stock after purchasing an additional 60,000 shares during the period. Affinity Asset Advisors LLC owned approximately 0.15% of Kymera Therapeutics worth $2,737,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Wellington Management Group LLP grew its stake in shares of Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock valued at $164,134,000 after purchasing an additional 689,547 shares during the period. Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 7.0% in the 1st quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock valued at $143,183,000 after purchasing an additional 344,080 shares during the period. Driehaus Capital Management LLC grew its stake in shares of Kymera Therapeutics by 4.6% in the 4th quarter. Driehaus Capital Management LLC now owns 1,390,372 shares of the company's stock valued at $55,935,000 after purchasing an additional 61,669 shares during the period. Deerfield Management Company L.P. Series C bought a new stake in Kymera Therapeutics during the 4th quarter worth approximately $23,856,000. Finally, Woodline Partners LP grew its position in Kymera Therapeutics by 2.3% during the 4th quarter. Woodline Partners LP now owns 537,428 shares of the company's stock worth $21,621,000 after acquiring an additional 12,334 shares during the last quarter.

Wall Street Analysts Forecast Growth

KYMR has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $60.00 price target (up from $54.00) on shares of Kymera Therapeutics in a research report on Thursday, June 26th. UBS Group decreased their price target on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. Oppenheimer restated an "outperform" rating and set a $53.00 price target (down from $56.00) on shares of Kymera Therapeutics in a research report on Friday, June 27th. Finally, BTIG Research restated a "buy" rating and set a $59.00 price target on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of "Buy" and a consensus target price of $58.76.

Kymera Therapeutics Price Performance

Shares of KYMR stock traded down $0.55 during trading hours on Friday, reaching $41.20. The company had a trading volume of 596,284 shares, compared to its average volume of 641,875. The company has a 50 day moving average of $43.75 and a 200 day moving average of $36.81. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of -11.87 and a beta of 2.18. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The business had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The business's quarterly revenue was down 55.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.58) EPS. As a group, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il acquired 317,167 shares of the company's stock in a transaction that occurred on Monday, June 30th. The shares were acquired at an average price of $44.00 per share, with a total value of $13,955,348.00. Following the purchase, the director owned 2,798,795 shares of the company's stock, valued at $123,146,980. This represents a 12.78% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Nello Mainolfi sold 30,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares in the company, valued at $32,363,618. The trade was a 4.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 in the last three months. 16.01% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.